Rezultati - Jeffrey A. Engelman

Refine Results
  1. 1
    <i>ALK</i> in Lung Cancer: Past, Present, and Future

    <i>ALK</i> in Lung Cancer: Past, Present, and Future od Alice T. Shaw, Jeffrey A. Engelman

    Izdano 2013
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    SnapShot: Non-Small Cell Lung Cancer

    SnapShot: Non-Small Cell Lung Cancer od Rebecca S. Heist, Jeffrey A. Engelman

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

    ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics od Carlos L. Arteaga, Jeffrey A. Engelman

    Izdano 2014
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors

    The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors od Jeffrey A. Engelman, Lewis C. Cantley

    Izdano 2006
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

    Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer od Jeffrey A. Engelman, Pasi A. Jänne

    Izdano 2008
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  6. 6
    Chemoprevention Meets Glucose Control

    Chemoprevention Meets Glucose Control od Jeffrey A. Engelman, Lewis C. Cantley

    Izdano 2010
    Polni tekst
    Carta
    Dodaj v priljubljene
    Shranjeno v:
  7. 7
    Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

    Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer od Matthew J. Niederst, Jeffrey A. Engelman

    Izdano 2013
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  8. 8
    Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

    Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers od Ryan B. Corcoran, Jeffrey Settleman, Jeffrey A. Engelman

    Izdano 2011
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  9. 9
    Genetic Changes in Squamous Cell Lung Cancer: A Review

    Genetic Changes in Squamous Cell Lung Cancer: A Review od Rebecca S. Heist, Lecia V. Sequist, Jeffrey A. Engelman

    Izdano 2012
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  10. 10
    The PI3K Pathway As Drug Target in Human Cancer

    The PI3K Pathway As Drug Target in Human Cancer od Kevin D. Courtney, Ryan B. Corcoran, Jeffrey A. Engelman

    Izdano 2010
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  11. 11
    Specific Inhibitors of p38 Mitogen-activated Protein Kinase Block 3T3-L1 Adipogenesis

    Specific Inhibitors of p38 Mitogen-activated Protein Kinase Block 3T3-L1 Adipogenesis od Jeffrey A. Engelman, Michael P. Lisanti, Philipp E. Scherer

    Izdano 1998
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  12. 12
    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics od Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber

    Izdano 2015
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  13. 13
    Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists

    Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists od Brent N. Rexer, Jeffrey A. Engelman, Carlos L. Arteaga

    Izdano 2009
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  14. 14
    Targeting the PI3K signaling pathway in cancer

    Targeting the PI3K signaling pathway in cancer od Kwok‐Kin Wong, Jeffrey A. Engelman, Lewis C. Cantley

    Izdano 2009
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  15. 15
    Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers

    Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers od Jeffrey A. Engelman, Xiao Lan Zhang, Michael P. Lisanti

    Izdano 1998
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  16. 16
    The present and future of PI3K inhibitors for cancer therapy

    The present and future of PI3K inhibitors for cancer therapy od Pau Castel, Eneda Toska, Jeffrey A. Engelman, Maurizio Scaltriti

    Izdano 2021
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  17. 17
    Tyrosine kinase gene rearrangements in epithelial malignancies

    Tyrosine kinase gene rearrangements in epithelial malignancies od Alice T. Shaw, Peggy P. Hsu, Mark M. Awad, Jeffrey A. Engelman

    Izdano 2013
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  18. 18
    Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3)

    Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) od Jeffrey A. Engelman, Xiao Lan Zhang, Ferruccio Galbiati, Michael P. Lisanti

    Izdano 1998
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  19. 19
    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin od Matthew G. Oser, Matthew J. Niederst, Lecia V. Sequist, Jeffrey A. Engelman

    Izdano 2015
    Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  20. 20
    Targeted Down-regulation of Caveolin-3 Is Sufficient to Inhibit Myotube Formation in Differentiating C2C12 Myoblasts

    Targeted Down-regulation of Caveolin-3 Is Sufficient to Inhibit Myotube Formation in Differentiating C2C12 Myoblasts od Ferruccio Galbiati, Daniela Volonté, Jeffrey A. Engelman, Philipp E. Scherer, Michael P. Lisanti

    Izdano 1999
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: